美国人是怎么用医保看病的

2016-01-08 ERIC 港股挖掘机

这几天,中国人退休后可以要继续买医保的传言闹得沸沸扬扬,成为舆论关注的焦点。无论你生活在哪个国度,拥有一份合适好用的医疗保险都十分重要。即便是在经济发达、科技先进的美国也不例外。 中国人谈及美国医疗制度,总觉得外国的月亮更圆。然而,实际情况是,在奥巴马医改计划2010年3月获国会通过之前,美国可以说是全民医疗服务非常落后的发达国家之一,因为当时美国并没有全民医保计划。 究其

这几天,中国人退休后可以要继续买医保的传言闹得沸沸扬扬,成为舆论关注的焦点。无论你生活在哪个国度,拥有一份合适好用的医疗保险都十分重要。即便是在经济发达、科技先进的美国也不例外。

中国人谈及美国医疗制度,总觉得外国的月亮更圆。然而,实际情况是,在奥巴马医改计划2010年3月获国会通过之前,美国可以说是全民医疗服务非常落后的发达国家之一,因为当时美国并没有全民医保计划。

究其原因,出于固有传统价值观的影响,大多数美国人坚定不移地相信政府提供医保等于“社会主义”。与此同时,美国人又对北欧国家如瑞典、挪威的高福利模式嗤之以鼻。因为美国是一个崇尚个人奋斗的国家,大部分美国人从小就被教育:个人不应该靠政府,政府没有提供社会保障安全网的义务。

那么,问题来了,在医保体系并不健全的美国,老百姓特别是退休后的老人是怎么靠医保看病的?除了医保体系之外,美国人的健康还靠哪些机制来保障?

美国医疗真的是高福利吗?

有些在美国治过病的中国人,也许会开心地说在美国看病啥钱都没有交,手术做了、药也吃了、院也住了,大谈美国医疗的“高福利”。

但实际情况是什么呢?中国一般是先交钱再看病,但美国医疗靠保险,是先看病后交钱。

有些来美国探望儿女的中国父母,生了大病也选择去看急诊(美国医院不能拒绝急诊病人),看完就走,玩“蒸发”,美国不用“父债子还”。不少墨西哥或其他周边国家的人,到医院急诊去生孩子,拿到美国出生证后,就再找不到人了。

美国财政每年要花一大笔钱来贴补这样的医疗亏损。加州政府之所以比其他州经济更为紧张,原因之一就是外来人口太多。

这种种现象,折射出美国这个移民国家医疗保障体系的漏洞和无奈。

美国医保类型面面观

美国的医疗保险有4大块:医险,药险,牙险,视险。每种险可以单独分开来买,其中医药保险是最主要的部分,有两大类:一是PPO(preferred

provider organization) ,二是HMO(Health Maintenance Organization)。

前者每月交的保险费高,可以随便去任何医院看任何医生,看病时自己要付20%;后者,每月交的保费稍低,只能到指定的医院看指定的医生,每次看诊只需要交约20美元。这两种保险的药费都是另算的,根据保险条款约定付自己应该付的份额。

采用HMO形式,会发生以下情形:比如,保险公司会把500人包给一个医生,每年给医生10万美金的固定收入。这样的设置,医生看的病人越多,相对赚的钱越少。因为医生拿的钱是固定的,医生最希望什么病人都不看,那样的话一年能白赚10万。

若采用PPO方式,保险公司则按病人给医生钱,医生看一个病人拿一个病人的钱。若没病人的话,医生就一分钱也赚不到。但美国医疗资源又是有限的,很容易造成僧多粥少的局面。

需要指出的是,美国各种医疗保险中都有一个OOPM条款(Out-of-pocket maximum )。即无论你的医疗费用多高,

他们会规定一个年度医药费的上限。超过这个上限的费用,个人不用支付。这个是很重要的是条款,有了OOPM,一般家庭才不会因病致贫,更不会因病破产。

美国人都怎么买医保

1、雇主购买的群体保险

在美国,最常见的是雇主买的群体保险,也就是你所在的企业或机构购买的医疗保险。

雇主支付保险公司费用,让保险公司来做以下事情:一是根据保险条例来付账给医疗供应商;二是为员工提供医疗网络:

保险公司一般能够在医疗供应商那里拿到比较好的折扣,构建自己的医疗网络系统,对医生质量进行把关,口碑不好的医生,保险公司有可能将其清除出自己的网络。三是为员工提供客户服务,例如法律条款咨询、福利变更通知、听取客户意见、电话专业咨询等;四是进行保健管理,主要是控制员工滥用保险,防止低效的医疗服务,进而减少开支。

大型机构。规模大点的公司(1000人以上),保险是自保的。所谓“自保”,是指保险费根据员工医疗费实际花多少钱而定。这样的大公司必须和保险公司直接签合同,让保险公司来管理保险和医疗服务的细节。保险公司一般会收取大概10%

左右的管理费。

例如,一个公司有5000员工,还有5000个家属,共10000人。一年间这一万人的医疗费用是3500万美金,保险公司便收取350万美金的管理费,合计费用就是3850万美金,平均到每人,一年的保险费就是3850美元。

中型机构。数百人规模的公司,保险费与员工过去医疗费用有关系,但并不是100%相关。保险公司除了提供上述服务外,还需要整一套系统来算保险费应该收多少,因为有风险,所以一般保险费会更贵一些。

小型机构。而更小的公司,百人以内的,保险费可能就与员工医疗费用无关了。保险公司会参照大量此类小公司以往的医疗费用来决定收多少保险费,就是所谓的集合风险。

在美国,很多员工其实并不知道真正的保险费是多少。因为很多公司并没有公开全部保险费,只是告知员工个人需要付的部分。

这就会产生一种情况:例如,去年一个家庭保险费每月是1000元,公司付800元,员工付200元。今年保险费涨到1100元(涨10%),公司还只是愿意付800元,却告知员工付300元。那么员工就会错误地认为自己的保险涨了50%。

2、个人购买的医疗保险

个人保险 (individual insurance),也即是自己去找保险公司买的医疗保险。

一般来说, 同样的权益下,自己买的医疗保险要比雇主买的医疗保险服务要差一些:核保要求和共付医疗费的金额更高一些,免赔额也更高一些。

保险费相对也更高些。因为保险公司从风险考量上,比起雇主买保险的公司员工,自己去购买个人保险的,往往健康状况相对要差一点。

此外,由于保险是卖给个人,所以没有产生规模经济效应,保险公司就要抬高管理费用,给保险代理的佣金也要相应要高一些。

3、服务特殊人群的Medicare和Medicaid

Medicare是美国国家老年人医疗保险计划,给老人和某些残疾人用的;而Medicaid

是医疗补助计划,这是联邦政府和州政府联合采取的一个方案,主要是给穷人及其子女使用的。

在美国人的普遍意识中,只有平时努力工作交税,才应享有高质量医保;低收入吃福利的只应享有基本的医保。

联邦政府规定贫困的小孩、孕妇、老人(65岁以上)才有资格享有上述福利。这意味着绝大多数的中产阶级享受不到这个“政府福利”,而这福利又在很大程度上由中产阶级买单。这就很不公平。

人们会以为,不付钱的medicaid一般不应享受到很好的医疗服务。事实上,在美国有的medicaid居然比私人保险还要好许多,而且medicare被滥用的例子屡见不鲜。媒体上经常有报道称,在美国佛州养老的富人三天两头往medicare医生那儿跑,做各种昂贵的检查保健。这是一种浪费。

推广全民医保——美国医改也是头痛的事

很难想象吧?在奥巴马医改计划2010年3月获国会通过之前,美国一直没有全民医保计划。这意味着,之前很多美国人并没有医疗保险。

所以,历尽千辛万苦终于推出的奥巴马健保计划(ACA)改革,肩负着为没有医疗保险的美国公民提供“可以负担得起”的医疗保障的历史使命。ACA规定所有人都必须买保险,规定保险公司不能因为保险人身体不好而拒保,否则就要接受罚款。

因为要求所有人都买保险,从而把很多原来没有保险的人推入到保险的池子里面来。然而,ACA推出以来,美国医疗保险公司纷纷表示,通过奥巴马健保法获得保险的客户比原来的健康水平更差、疾病更多,造成很多公司收支不平衡,出现运营亏损。部分医保公司将寻求在2016年大幅提高医疗保险费,平均增幅2到4成左右,甚至更多。

这已经违背了奥巴马健保计划的初衷,所以,新健保法带来的冲击一时半会无法平息,而美国社会也将继续探索美国式的全民医保之路。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-12 medsic

    应该学习各自优点,

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-12 medsic

    应该学习各自优点,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-12 medsic

    支持楼上观点

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-12 medsic

    各有优势,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-12 medsic

    各有优势,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-12 medsic

    应该相互学习,,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-12 medsic

    应该相互学习,,

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1910785, encodeId=deb81910e85ff, content=<a href='/topic/show?id=fa64e9729d1' target=_blank style='color:#2F92EE;'>#美国人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79729, encryptionId=fa64e9729d1, topicName=美国人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Sat Jul 30 14:57:00 CST 2016, time=2016-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56384, encodeId=38ee563842b, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56385, encodeId=9dca5638572, content=应该学习各自优点,, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56386, encodeId=12d35638645, content=支持楼上观点, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:15:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56380, encodeId=32125638055, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56381, encodeId=1fc056381fb, content=各有优势,, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56382, encodeId=16865638250, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=56383, encodeId=593b56383c3, content=应该相互学习,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Tue Jan 12 13:14:00 CST 2016, time=2016-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55534, encodeId=e2bb55534ea, content=能比吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 10 20:42:00 CST 2016, time=2016-01-10, status=1, ipAttribution=)]
    2016-01-10 xyfg98

    能比吗

    0

相关资讯

美女医生:我亲眼目睹的美国医闹

最近医闹事件此起彼伏,在媒体上频频见报,这一期就聊聊医闹的话题。Azure Sun(微博号@Azure豹)是一位美女牙医,她的行医历程跨越了大半个地球,最后定居于新加坡。不久前,她写了一篇她亲身目睹美国“医闹”的文章,征得了她的同意,本期发出来与大家分享,看看美国的医闹是什么情况,又如何收场。 首先介绍一下Azure Sun,她是美国德州大学医学中心牙科学院牙科博士,美国南加州大学牙科学

Obstet Gynecol:生孩子就是鬼门关走一趟,即使在美国也如此

目的:估计2006至2010间全国性普查的妊娠相关死亡率的,并调查美国的妊娠相关死亡的原因及特点。方法:我们使用从怀孕死亡率监测系统获取的数据,计算妊娠相关死亡率,按四种种族的不同年份及不同年龄分组:非西班牙裔白人,非西班牙裔黑人,西班牙裔,其他。我们将1987年的数据与 2006-2010年的数据作对比,通过统计妊娠结局研究妊娠死亡的相关原因。结果:2006-2010年的妊娠相关死亡率为每10万

众说:学习美国移动医疗绝不能照搬

在医患供需严重不匹配的市场,医生用户才是移动医疗业务最重要的资源和价值来源。 美国的移动医疗一直以来都是中国移动医疗学习的标杆,最近一年一度的移动医疗大会mHealth移动医疗峰会在美国召开,中美间移动医疗间的差异再次成为话题热点。在过去的2014年中,美国医疗行业输出在GDP占18%,中国去年只占5.3%左右,可以看出中国医疗市场蕴藏着的巨大潜力。究竟美国的移动医疗成功的秘诀在于哪里?而中

涨姿势:中美排名前十位大学对比:中国大学“输”在哪

美国目前仍被公认为是世界上的创新大国、强国:世界上70%的专利出自美国,无论是诺贝尔奖得主人数,还是世界一流大学的数目,美国都遥遥领先。更值得注意的是,世界上很多重大的、具有突破性意义的科研成果都来自美国。它们不一定都是由美国土本学生创造的,实际上,更多是由外国学生在美国大学从事研究后而创造出来的。 学生质量、教学设施、办学经费,师资队伍、管理体系、办学理念……在这些“看得见”的分类

美1.44亿美元研究环境对儿童健康影响

不久前,美国国立卫生研究院(NIH)宣布,拟在2016财年安排1.44亿美元,设立“环境对儿童健康结果的影响”(ECHO)重大研究计划,资助新工具和方法的开发,用于更有效地研究儿童从子宫孕育到出生几年以后的环境因素对其健康和发育的影响。 从某种程度上说,ECHO 计划也是NIH对已于2014年12月终止的“国家儿童研究”计划的延续。环境因素是全球范围内妇女儿童发病和死亡的主要诱导因素,这些因素包

评论:一起发生在美帝的中国医闹

昨天网上传一个消息,叫做“一起发生在美帝的中国医闹”。信息嘛,就是微信截屏。传播的人包括一名微博小v,认证信息是医生。这则信息相信的很多,但是,你用头脑或者脚趾头想想,那不可能是真的。我现在就来评这则消息,并且上纲上线一下对中国医疗环境做下评论。这信息先说某男士在美国医闹,警察来了还掐护士脖子然后被警察用枪托把“手臂硬生生的砸断了”。这位警察是大力神还是带着三八大盖来上班的啊?美国警察使用暴力毫不